Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532
Cancer · 2024
DOI: 10.1002/cncr.35084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Nicholas Evageliou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Kidney Neoplasms, Wilms Tumor. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, St. Baldrick's Foundation.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
The prognostic impact of positive lymph nodes (LN+) and/or singular loss of heterozygosity (LOH) of 1p or 16q were assessed in children with stage III favorable histology Wilms tumor (FHWT) enrolled on AREN0532 or AREN03B2 alone. Patients and Methods A total of 635 stage III FHWT vincristine/dactinomycin/doxorubicin (DD4A)–treated patients met inclusion criteria. Event‐free survival (EFS) and overall survival are reported overall and by LN sampling, LN status, LOH 1p, LOH 16q, and a combination of LN status and singular LOH. Patients with unknown or positive combined LOH of 1p and 16q status and AREN03B2‐only patients with unknown outcomes or treatment other than DD4A were excluded.
Results
EFS did not differ by study, supporting pooling. Lack of LN sampling (hazard ratio [HR], 2.12; p = .0037), LN positivity (HR, 2.78; p = .0002), LOH 1p (HR, 2.18; p = .0067), and LOH 16q (HR, 1.72; p = .042) were associated with worse EFS. Compared with patients with both LN– and LOH–, those with negative nodes but positive LOH 1p or 16q and those with LN+ but LOH– for 1p or 16q had significantly worse EFS (HR, 3.05 and 3.57, respectively). Patients positive for both LN and LOH had the worst EFS (HR, 6.33; overall group factor, p < .0001).
Conclusion
Findings confirm LN+ status as an adverse prognostic factor amplified by presence of singular LOH 1p or 16q, supporting study of intensified therapy for patients with LN+ in combination with singular LOH in a prospective clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Biostatistics, University of Southern California and Children's Oncology Group, Monrovia, California, USA.
- Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.
- Department of Pathology and Laboratory Medicine, The Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois, USA.
- Department of Radiation Oncology, Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, USA.
- Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Nicholas Evageliou, James Geller, Arnold Paulino, Andrew J Murphy, Peter F Ehrlich
Förderung
- NCI NIH HHS
- National Cancer Institute
- St. Baldrick's Foundation
Zitieren
APA
Evageliou, N., Renfro, L. A., Geller, J., Perlman, E., Kalapurakal, J., Paulino, A., Dix, D., Eklund, M. J., Murphy, A. J., Romao, R. L. P., Ehrlich, P. F., Varela, C. R., Vallance, K., Fernandez, C. V., Dome, J. S., & Mullen, E. A. (2024). Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532. Cancer. https://doi.org/10.1002/cncr.35084
Vancouver
Evageliou N, Renfro LA, Geller J, Perlman E, Kalapurakal J, Paulino A, et al. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532. Cancer. 2024. doi:10.1002/cncr.35084
BibTeX
@article{Evageliou2024,
author = {Evageliou, Nicholas and Renfro, Lindsay A and Geller, James and Perlman, Elizabeth and Kalapurakal, John and Paulino, Arnold and Dix, David and Eklund, Meryle J and Murphy, Andrew J and Romao, Rodrigo L P and Ehrlich, Peter F and Varela, Carly R and Vallance, Kelly and Fernandez, Conrad V and Dome, Jeffrey S and Mullen, Elizabeth A},
title = {Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children’s Oncology Group Studies AREN03B2 and AREN0532},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35084}
}
EUVIMED